Summit Therapeutics Inc. (SMMT) — Financial statements
Income statement, balance sheet, and cash flow for Summit Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00↓100.0% | 0.58↓56.4% | 1 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00↓100.0% | 0.58↓56.4% | 1 | |
| Operating Expenses | ||||||
| R&D Expenses | 538↑306.0% | 132↓70.9% | 455↑958.4% | 43↓31.8% | 63 | |
| General & Administrative Expenses | 557↑1051.5% | 48↑103.6% | 24↑7.3% | 22↑26.7% | 17 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 557↑1051.5% | 48↑103.6% | 24↑7.3% | 22↑26.7% | 17 | |
| Other Expenses | 0.00↑100.0% | -0.25↑68.1% | -0.79↑84.0% | -5↑68.3% | -16 | |
| Operating Expenses | 1,094↑506.3% | 181↓62.3% | 478↑694.2% | 60↓7.5% | 65 | |
| Total Costs & Expenses | 1,094↑506.3% | 181↓62.3% | 478↑694.2% | 60↓7.5% | 65 | |
| Operating Results | ||||||
| Operating Income | -1,094↓506.3% | -181↑62.3% | -478↓701.9% | -60↑6.4% | -64 | |
| Depreciation & Amortization | 0.15↑105.6% | 0.07↓54.3% | 0.16↓85.1% | 1↑4.9% | 1.00 | |
| EBITDA | -1,079↓540.8% | -168↓142.6% | -69↓34.6% | -52↑17.8% | -63 | |
| EBIT | -1,080↓540.6% | -169↓142.1% | -70↓32.3% | -53↑17.4% | -64 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 5↑178.9% | -6↓109.8% | -3↓1286.5% | -0.21 | |
| Interest Income | 0.00↓100.0% | 13↑29.4% | 10↑587.6% | 2 | 0.00 | |
| Interest Expense | 0.00↓100.0% | 9↓47.2% | 16↑274.0% | 4↑2012.8% | 0.21 | |
| Non-Operating Income | -15↓23.8% | -12↑97.1% | -409↓5733.4% | -7 | 0.00 | |
| Other Income / Expenses | 15↑296.7% | 4↑190.3% | -4↑25.2% | -6↓209.9% | -2 | |
| Income Before Tax | -1,080↓510.7% | -177↑63.4% | -482↓640.2% | -65↑0.5% | -66 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -1,080↓510.7% | -177↑63.4% | -482↓640.2% | -65↑0.5% | -66 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -1,080↓510.7% | -177↑63.4% | -482↓640.2% | -65↑0.5% | -66 | |
| Bottom-Line Net Income | -1,080↓510.7% | -177↑63.4% | -482↓640.2% | -65↑0.5% | -66 | |
| EPS (Basic) | -1.44↓476.0% | -0.25↑67.9% | -0.78↓129.4% | -0.34↑52.1% | -0.71 | |
| EPS (Diluted) | -1.44↓476.0% | -0.25↑67.9% | -0.78↓129.4% | -0.34↑52.1% | -0.71 | |
| Weighted Average Shares | 748↑4.7% | 714↑15.2% | 620↑222.5% | 192↑108.3% | 92 | |
| Weighted Average Diluted Shares | 748↑4.1% | 719↑16.0% | 620↑220.5% | 193↑109.6% | 92 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.